Trial Profile
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET [doxorubicin liposomal] Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2 [human epidermal growth factor receptor 2]-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Cephalon France; Teva Pharmaceutical Industries
- 11 Oct 2016 Primary endpoint (Pathological complete response (pCR) in breast, upon histologic examination) has not been met according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
- 08 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.